Cannabis Bioscience International Holdings, Inc.
Cannabis Bioscience International Holdings, Inc.
Your view on CBIH
Overview
What the company does, where it operates, and who runs it.
About Cannabis Bioscience International Holdings, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Dante Picazo
- Headquarters
- 6201 Bonhomme Road, Houston, TX, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Dante Picazo
- Headquarters
- 6201 Bonhomme Road, Houston, TX, US
China Infrastructure Construction Corp. provides educational systems that focuses on medical cannabis in the United States and Latin America, and worldwide through online education.
The company offers services in the therapeutic areas of clinical trials; and relating to sleep disorders, including resulting infertility, through its fertility and sleep center in Houston, Texas. It also offers education, consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University.
The company was founded in 2003 and is headquartered in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cannabis Bioscience International Holdings, Inc., and the rating behind it. CBIH last traded at $0.0004; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cannabis Bioscience International Holdings, Inc.. Starting points for Cannabis Bioscience International Holdings, Inc.: beta 1.87 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cannabis Bioscience International Holdings, Inc.. Cannabis Bioscience International Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cannabis Bioscience International Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cannabis Bioscience International Holdings, Inc.. Cannabis Bioscience International Holdings, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cannabis Bioscience International Holdings, Inc. valued side by side against its closest peers. Cannabis Bioscience International Holdings, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cannabis Bioscience International Holdings, Inc., and how their positions are changing. At a $5.2M market value, institutional positions materially move Cannabis Bioscience International Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cannabis Bioscience International Holdings, Inc. executives and directors. Shares of Cannabis Bioscience International Holdings, Inc. have traded between $0.0003 and $0.0008 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cannabis Bioscience International Holdings, Inc.. Cannabis Bioscience International Holdings, Inc. is a $5.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cannabis Bioscience International Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cannabis Bioscience International Holdings, Inc.. Coverage tracks Cannabis Bioscience International Holdings, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.